TY - JOUR
T1 - Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib
T2 - a multi-country retrospective chart review study
AU - Cortes, Jorge
AU - Huynh, Lynn
AU - Mendelson, Estella
AU - Brandt, Patricia
AU - Dalal, Darshan
AU - DerSarkissian, Maral
AU - Cortina, Diego
AU - Narkhede, Sahil
AU - Sheng Duh, Mei
N1 - Funding Information:
This research was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, US. The authors thank Giuliana Zaccardelli for her analytical support and Camara Sharperson and Jessica Marden for their writing and editorial support to the study.
Publisher Copyright:
© 2019, © 2019 Analysis Group, Inc.
PY - 2020/1/2
Y1 - 2020/1/2
N2 - Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48%]) or dasatinib (N = 145 [52%]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95% CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.
AB - Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48%]) or dasatinib (N = 145 [52%]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95% CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.
KW - Chronic myeloid leukemia
KW - deep molecular response
KW - nilotinib
KW - targeted therapies
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85070889545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070889545&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1644332
DO - 10.1080/10428194.2019.1644332
M3 - Article
C2 - 31409168
AN - SCOPUS:85070889545
SN - 1042-8194
VL - 61
SP - 98
EP - 107
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -